Clinical trial services and drug development company Ergomed has entered a co-development agreement with Asarina Pharma to conduct the Phase IIb clinical trial of Sepranolone (UC1010) to treat premenstrual dysphoric disorder (PMDD).
PMDD is characterised by cyclic symptoms such as depression, anxiety, irritability, mood lability and loss of emotional control consistently at the latter part of the menstrual cycle, affecting a woman's personal and professional life.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The disorder is experienced during the fertile period beginning from menstruation until menopause.
Under the agreement, Ergomed will conduct Asarina’s multicentre, multinational, randomised Phase IIb clinical trial next year and will jointly invest into the trial in return for an equity stake in Asarina.
Ergomed CEO Dr Miroslav Reljanovic said: “We are delighted to be the co-development partner for Asarina as it embarks upon its Phase IIb clinical trial programme for Sepranolone, which has the potential to be a first-in-class therapy for this serious disease.
“This further expands the number of pipeline opportunities where we share in the potential upside as a drug is successfully developed through leveraging our expertise and experience in providing clinical trial services to support such development.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAsarina’s proprietary Sepranolone is an endogenous, small molecule acting as a GABA-A modulating steroid antagonist (GAMSA).
Sepranolone has demonstrated its safety, efficacy and pharmacokinetics profile in an exploratory, double-blind, randomised, placebo-controlled, clinical phase I/II study conducted by Asarina on 120 women with PMDD.
